GESYNTA PHARMA AB 

Target group

PhD students (1 month internship)

About the company

Gesynta Pharma is a clinical-stage pharmaceutical company developing innovative treatments by targeting mPGES-1*, an important pro-inflammatory enzyme. Gesynta Pharma’s research originated at Karolinska Institutet in Sweden.

The company’s leading compound, vipoglanstat, is a selective mPGES-1 inhibitor currently in Phase 2 clinical trials for endometriosis. It is being developed as a new non-hormonal, non-opioid treatment for the condition – a painful, chronic inflammatory disorder affecting about 10% of women of reproductive age.

*mPGES-1: microsomal Prostaglandin E Synthase-1

The Project

Project Title

Fertility Considerations in the Clinical Development of a Non-Hormonal Endometriosis Treatment

Project Description

Endometriosis primarily affects women of reproductive age, and fertility considerations are often clinically relevant. Gesynta’s lead candidate is currently in Phase II clinical development as a non-hormonal non-opioid treatment for endometriosis, designed to reduce inflammation and pain and with potential for disease modification.

The aim of this project is to explore how fertility-related aspects may be relevant in the clinical development of this therapy and how such considerations could be reflected in ongoing or future development planning.

The project may include:

• Review of publicly available clinical trial designs in endometriosis to understand how fertility-related endpoints are typically addressed
• Review of the therapy’s mechanism of action and its potential implications for fertility
• Synthesis of findings to identify practical considerations including exploratory endpoints that may be relevant for ongoing or future clinical development

Expected outcomes

At the end of the internship, the student is expected to deliver a structured internal summary (format to be agreed upon) outlining:

• Key observations regarding how fertility is addressed in current endometriosis clinical development
• Identification of fertility-related aspects that may warrant consideration
• Practical summary that will support internal discussions on continued clinical development design and planning

Location

Wallingatan 24, Stockholm, Sweden

Time period

Spring–Autumn 2026 (exact timing to be agreed)

The candidate

We are looking for a PhD student in life sciences with a strong scientific foundation and a genuine interest in the clinical drug development process. Desired qualifications:

• Ongoing PhD studies in reproductive biology, endocrinology, pharmacology, or a related life science field
• Strong ability to critically evaluate and synthesize scientific and clinical literature
• Structured and analytical mindset, with the ability to translate complex data into clear conclusions
• Ability to work independently and manage a focused project within a defined timeframe
• Interest in understanding how scientific evidence informs clinical development decisions

Contact information

Name: Gunilla Ekström

Email: gunilla.ekstrom@gesynta.se

Telephone: 0733542058

Company website: https://www.gesynta.se/